주간보건산업동향 진흥원(정보통계센터) 121126(1)
TRANSCRIPT
_()_121126(1).hwp. . .
1 : 2 : (43)
2012. 11. 26
1.
GDP ‘11.3/4 ‘12.3/4
() 9 10
() 9 10
(/$) 11.14 11.21
(GDP) ‘12 3 2.0%
* ’12.2 0.2% ( , )
() , (30.4→37.1$)
()
, (1,084.9→1,083.2/$)
* ( )
() / (6.4→6.7%)
* 1.4% , 13.3%
< : (‘11) >
(530$), 1.5%(170$), 0.3%(40$), 0.5%(60$)
() 10$, GDP 14.3%
GDP ()
()
5,701 (8.1)
942 (1.3)
296 (0.4)
243 (0.3)
2821 (4.0)
89 (0.1)
n.a.. n.a..
53 (4.8)
17 (1.5)
4 (0.3)
6 (0.5)
42 (3.8)
- 2 -
(%) (%)
(, %)
1237.1 79.4 1,333.1 -5.6 1,253.7 -7.1 24,244 1,332 1,195 1,884 -0.5
65.7 -25.3 25.3 8.4 50.6 -9.8 403 *
46.2 81.0 n.a. n.a.
15.6 -9.6 5.0 10.8 14.5 4.9 73 11.1 21.9 4,171 -3.8
3.4 -3.2 6.5 15.1 9.7 11.5 32 1.0 2.2 1,451 -13.4
6.4 -0.5 2.6 22.0 3.1 3.0 23 5.4 20.5 n.a. n.a.
40.3 -12.1 11.3 1.5 23.4 -23.7 276 28.7 36.3 3,858 -0.6
1.0 -2.6 1.0 -15.6 3.6 -1.6 13 2.5 11.8 n.a. n.a.
* 43.4 83.7
** 70( 587), 20( 1,958), 10
( 587), 48( 23,774, 1(KT&G, 424))
*** 2012.11.2
() 3/4 8.4% ,
9.8% , 25.3*
* ’09 (): (’09)7.03→ (’10)7.0 → (’11)7.53
(10.8%↑) (15.1%↑), (22.0%↑)
() 11.21 (3.8%) ,
(13.4%)
(36.3), (20.5), (21.9), (2.2)
- 3 -
() (43) 28 , 7
(11.19 6.18 , 8 )
(17,950→39,250, 118.7%),
(59,900→124,000, 107.0%), (13,150→24,000, 82.5%)
() 22.7% (18.8→23.0)
(2,342→5,122 118.7%), (4,724
→9,780, 107.0%), (917→1,674, 82.5%)
(6.18 , %) (6.18 , %)
- 4 -
(Wip1+(nutlin-3)) (11.19)
* 'Science Signaling'
*
‘ ’
(11.19)
’ (11.15)
‘
(: )’ (11.1)
‘+ ’‘)’ (11.20)
… 7 (11.15)
* (MabThera)
* :
‘(: )’ 10 66
(11.20)
GMP 37.4 (11.20)
(11.14)
* ·
MOU (11.14)
- 183 (11.15)
1 (11.16)
(Oxaliplatine), (irinotecan),
.
(11.14)
FDA (11.20)
'RTS,S', (11.20)
* 3 1 … 3
, ‘’(NEJM)
‘’ (11.19)
* 9 3 6∼24 2
BMS
EU (11.21) * FDA 3
(Biocon)
(11.19)
(Flucelvax)’ FDA (11.21)
B ‘Bexsero’ EU …‘13
1 3,300 (11.17)
Biocon BMS ‘IN-105' (11.16)
Sanofi ‘Lyxumia(: )’ ‘Zaltrap
(: )’ EU (11.18)
*
…(Journal of Women's Health)
Reckitt
Benckiser
2 14 (11.21)
Allergan SkinMedica 3.5 …
(11.16)
98.9% (11.20)
* 60% , 70%
… 525
BMJ, ‘(Tamiflu)’ (11.12)
* (BMJ) ‘(Tamiflu)’
- 6 -
(11.19)
3 ‘(BalPro)' , (11.15)
‘(Mindray Medical) DC-3'
(11.19)
* ,
‘’ … 20
(11.16)
'3 Flow (3 Flow
Aspiration Catheter)' (11.15)
FDA (11.16)
array)' (11.19)
* 100∼2000
… ,
‘Portica
TAVI valve' CE (11.19)
Cerner 'FetaLink+' FDA (11.13)
*
Kips Bay ‘eSVS’ FDA
(11.12)
pumps' (11.14)
T2
Biosystems
2 (11.14)
Teleflex ‘The Nylus PICC' FDA (11.15)
Abiomed ‘Impella RP' FDA (11.15)
Quantel ‘SupraScan 577 laser system' FDA (11.16)
Vitacon ‘VitaScan LT USB Scanner' FDA (11.16)
Westhouse
Medical
52% (11.19)
Defibtech (11.13)
’ (11.19)
MOU (11.15)
·
'· Web-EDI '
(11.15)
‘ PW-A7300’ (11.9)
* 26 , ‘ ’
,
* ‘ ’(13, )
(11.14)
(11.19)
(11.19)
, ,
LG ‘ ’ (11.19)
* 100%
(11.7)
* 43 30%
, 70%
* ‘(The Safe Chemicals Act)’ ,
(Merck)
(TANC)’ (11.10)
(SkinMedica)’ 35000 (11.19)
-7' (11.14)
* NAPQI ,
…‘Antioxidants and Redox Signaling(ARS)’
- 9 -
(11.20)
*
…‘ ’
, ‘Development’
* (PNAS)
(), (11.14)
* 0.95 0.95
2.8 , Gleason
…‘Int Braz J Urol’
‘ ’ (11.15)
* ‘1 ’, 2
‘’, (11.13)
* Biological & Pharmaceutical Bulletin
, (11.19)
* 3 , 40% …
(Dermatologic Surgery)
* OECD
MOU (11.15)
(11.20)
* ‘’ GS25
, 10 5 (11.19)
* 10 OECD , · OECD 6:4
9:1
* (iPS) (ES)
99% …' '
- 10 -
* 'IL-10'
* 5-HTT …
(Canadian Journal of Psychiatry)
(11.20)
* SFRP-4 ,
SFRP-4 …(Cell
Metabolism)
“ ”(11.12)
* …
(Archives of Internal Medicine)
AMC) (11.13)
(11.13)
*
…
10 (11.16)
* , …
- 11 -
* : ( 6.55%)
(11.20)
'' 13 11 (11.15)
‘ ’ (11.16)
* : ‘ ’ 7
2013 (11.15)
* · 4 …' '
'2012 ' 66 (11.19)
* 4, · 2 …16
,
25 (11.28)
3) R&D ()
4) .()
5) 2013 ()
, 4 ' '(11.23, )
* 5% R&D , 10 6
)
* : ‘ ’
‘1 (CEO) ’ (11.21)
.
(11.14)
‘ (DMF) ’ (11.16)
(11.20, 27)
* , -
,
(11.20)
* CYP2C19 , 60%
‘ ·· ’
(11.15)
, ‘·
’ (11.21, SFDA)
-, 6
(11.19)
… 4
, ‘1 ’ ·
(11.16)
· …
(11.21)
* 45,025 33,878
, (11.15)
* ,
(Affordable Care Act)’
, (compounding pharmacy)
(11.7)
In Drug Compound Act)’
- 13 -
, (fat tax) … (11.12)
* '11 10 1 16 ( 3) ,
, (11.5)
* ‘10 ’
… 18 3
- 60∼70
, iPS (11.5)
* iPS
5 , 10
, (iPS)
(11.6)
* '13 15
, (11.7)
* (10 ) 1 347
… (IHPS)
HIV (11.20)
* (PSTF), 15∼65
, ‘ ’ (11.1)
* (Auckland District Court) (Waitakere
District Court) ,
, SCI
PLoS One
,
NGO
(11.19, )
(11.28, )
(12.3, )
- , ‘2012 R&D ’(11. 26,
)
)
'(11.16, )
* , ’12 ’13
- , ‘ 2012 ’(11.21,
)
(11.20, )
’(11.19∼23)
- , ‘ (11.21,
)
(11.26, )
(11.19, )
* 14853 , 3016
- 15 -
9.1 7.1 10.9 -0.7 738 8.1 12.7 12.5 133
112,000. -2.2 18.0 26.0 2,303 1.0
7.1 10.8 8.5 -5.4 737 10.4 64.6 4.9 198
43,150. -7.2 9.7 26.0 1,337 6.4
7.0 -11.6 11.1 -7.3 587 8.4 3.2 15.1 121
149,000. -6.6 26.7 26.0 1,335 -2.8
6.7 2.8 7.9 -4.1 504 7.5 22.3 19.9 102
178,500. -5.6 21.6 26.0 1,511 -
5.1 -13.8 0.3 2.5 840 16.4 -2.5 10.2 143
129,500. 9.7789.6 26.0 1,919 0.9
2.8 54.0 65.3 5.9 1,376 49.4 43.9 45.4 1
26,000. 2.2 26.9 26.0 655 25.5
0.3 40.3 12.5 3.7 93 36.7 3.3 6.0 26
84,300. -2.8126.6 -260.7 117 20.6
0.1 51.7 -149 -4.7 464 480.2 1,447 2.2 315
5,290. -9.1 -8.1 -260.7 102 88.9
19
45
28,750. -4.5 74.5 86.9 791 6.3
1.0 -7.1 7.8 0.4 50 5.1 -6.4 1.5 165
10,250. -5.5 74.3 86.9 193 -40.8
0.4 15.7 23.4 -1.7 55 15.7 -1.3 1.8 131
18,100. 2.0 26.8 86.9 88 27.5
139
- 16 -
22.9 11.4 16.1 -0.4 734 3.2 10.8 76.9 33
1,315,000. 5.0 27.8 26.7 4,443 7.8
LG 20.0 14.2 12.1 0.1 435 2.2 11.1 103.1 22
660,000. 2.5 44.2 40.0 3,372 8.0
3.1 25.7 10.9 -1.2 20 0.7 33.7 8.7 156
84,000. -7.6 31.0 26.7 211 10.5
3.0 16.5 5.0 -1.1 144 4.8 11.2 5.8 185
29,800. -7.6 n.a. 26.7 659 2.6
1.8 13.7 4.9 -1.0 39 2.2 12.5 6.4 176
46,900. -8.6 55.4 26.7 368 16.5
* () 3 ‘11. 4. 1 ‘12. 3. 31
7,983 619.1 (7.7%)
11,203 434.8 (3.9%)
8,989 395.8 (4.4%)
5,017 73.7 (1.5%)
* R&D (, , , , ,
) +
, , )
- 17 -
(: , , %)
- - - - - -
1,000
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
1 : 2 : (43)
2012. 11. 26
1.
GDP ‘11.3/4 ‘12.3/4
() 9 10
() 9 10
(/$) 11.14 11.21
(GDP) ‘12 3 2.0%
* ’12.2 0.2% ( , )
() , (30.4→37.1$)
()
, (1,084.9→1,083.2/$)
* ( )
() / (6.4→6.7%)
* 1.4% , 13.3%
< : (‘11) >
(530$), 1.5%(170$), 0.3%(40$), 0.5%(60$)
() 10$, GDP 14.3%
GDP ()
()
5,701 (8.1)
942 (1.3)
296 (0.4)
243 (0.3)
2821 (4.0)
89 (0.1)
n.a.. n.a..
53 (4.8)
17 (1.5)
4 (0.3)
6 (0.5)
42 (3.8)
- 2 -
(%) (%)
(, %)
1237.1 79.4 1,333.1 -5.6 1,253.7 -7.1 24,244 1,332 1,195 1,884 -0.5
65.7 -25.3 25.3 8.4 50.6 -9.8 403 *
46.2 81.0 n.a. n.a.
15.6 -9.6 5.0 10.8 14.5 4.9 73 11.1 21.9 4,171 -3.8
3.4 -3.2 6.5 15.1 9.7 11.5 32 1.0 2.2 1,451 -13.4
6.4 -0.5 2.6 22.0 3.1 3.0 23 5.4 20.5 n.a. n.a.
40.3 -12.1 11.3 1.5 23.4 -23.7 276 28.7 36.3 3,858 -0.6
1.0 -2.6 1.0 -15.6 3.6 -1.6 13 2.5 11.8 n.a. n.a.
* 43.4 83.7
** 70( 587), 20( 1,958), 10
( 587), 48( 23,774, 1(KT&G, 424))
*** 2012.11.2
() 3/4 8.4% ,
9.8% , 25.3*
* ’09 (): (’09)7.03→ (’10)7.0 → (’11)7.53
(10.8%↑) (15.1%↑), (22.0%↑)
() 11.21 (3.8%) ,
(13.4%)
(36.3), (20.5), (21.9), (2.2)
- 3 -
() (43) 28 , 7
(11.19 6.18 , 8 )
(17,950→39,250, 118.7%),
(59,900→124,000, 107.0%), (13,150→24,000, 82.5%)
() 22.7% (18.8→23.0)
(2,342→5,122 118.7%), (4,724
→9,780, 107.0%), (917→1,674, 82.5%)
(6.18 , %) (6.18 , %)
- 4 -
(Wip1+(nutlin-3)) (11.19)
* 'Science Signaling'
*
‘ ’
(11.19)
’ (11.15)
‘
(: )’ (11.1)
‘+ ’‘)’ (11.20)
… 7 (11.15)
* (MabThera)
* :
‘(: )’ 10 66
(11.20)
GMP 37.4 (11.20)
(11.14)
* ·
MOU (11.14)
- 183 (11.15)
1 (11.16)
(Oxaliplatine), (irinotecan),
.
(11.14)
FDA (11.20)
'RTS,S', (11.20)
* 3 1 … 3
, ‘’(NEJM)
‘’ (11.19)
* 9 3 6∼24 2
BMS
EU (11.21) * FDA 3
(Biocon)
(11.19)
(Flucelvax)’ FDA (11.21)
B ‘Bexsero’ EU …‘13
1 3,300 (11.17)
Biocon BMS ‘IN-105' (11.16)
Sanofi ‘Lyxumia(: )’ ‘Zaltrap
(: )’ EU (11.18)
*
…(Journal of Women's Health)
Reckitt
Benckiser
2 14 (11.21)
Allergan SkinMedica 3.5 …
(11.16)
98.9% (11.20)
* 60% , 70%
… 525
BMJ, ‘(Tamiflu)’ (11.12)
* (BMJ) ‘(Tamiflu)’
- 6 -
(11.19)
3 ‘(BalPro)' , (11.15)
‘(Mindray Medical) DC-3'
(11.19)
* ,
‘’ … 20
(11.16)
'3 Flow (3 Flow
Aspiration Catheter)' (11.15)
FDA (11.16)
array)' (11.19)
* 100∼2000
… ,
‘Portica
TAVI valve' CE (11.19)
Cerner 'FetaLink+' FDA (11.13)
*
Kips Bay ‘eSVS’ FDA
(11.12)
pumps' (11.14)
T2
Biosystems
2 (11.14)
Teleflex ‘The Nylus PICC' FDA (11.15)
Abiomed ‘Impella RP' FDA (11.15)
Quantel ‘SupraScan 577 laser system' FDA (11.16)
Vitacon ‘VitaScan LT USB Scanner' FDA (11.16)
Westhouse
Medical
52% (11.19)
Defibtech (11.13)
’ (11.19)
MOU (11.15)
·
'· Web-EDI '
(11.15)
‘ PW-A7300’ (11.9)
* 26 , ‘ ’
,
* ‘ ’(13, )
(11.14)
(11.19)
(11.19)
, ,
LG ‘ ’ (11.19)
* 100%
(11.7)
* 43 30%
, 70%
* ‘(The Safe Chemicals Act)’ ,
(Merck)
(TANC)’ (11.10)
(SkinMedica)’ 35000 (11.19)
-7' (11.14)
* NAPQI ,
…‘Antioxidants and Redox Signaling(ARS)’
- 9 -
(11.20)
*
…‘ ’
, ‘Development’
* (PNAS)
(), (11.14)
* 0.95 0.95
2.8 , Gleason
…‘Int Braz J Urol’
‘ ’ (11.15)
* ‘1 ’, 2
‘’, (11.13)
* Biological & Pharmaceutical Bulletin
, (11.19)
* 3 , 40% …
(Dermatologic Surgery)
* OECD
MOU (11.15)
(11.20)
* ‘’ GS25
, 10 5 (11.19)
* 10 OECD , · OECD 6:4
9:1
* (iPS) (ES)
99% …' '
- 10 -
* 'IL-10'
* 5-HTT …
(Canadian Journal of Psychiatry)
(11.20)
* SFRP-4 ,
SFRP-4 …(Cell
Metabolism)
“ ”(11.12)
* …
(Archives of Internal Medicine)
AMC) (11.13)
(11.13)
*
…
10 (11.16)
* , …
- 11 -
* : ( 6.55%)
(11.20)
'' 13 11 (11.15)
‘ ’ (11.16)
* : ‘ ’ 7
2013 (11.15)
* · 4 …' '
'2012 ' 66 (11.19)
* 4, · 2 …16
,
25 (11.28)
3) R&D ()
4) .()
5) 2013 ()
, 4 ' '(11.23, )
* 5% R&D , 10 6
)
* : ‘ ’
‘1 (CEO) ’ (11.21)
.
(11.14)
‘ (DMF) ’ (11.16)
(11.20, 27)
* , -
,
(11.20)
* CYP2C19 , 60%
‘ ·· ’
(11.15)
, ‘·
’ (11.21, SFDA)
-, 6
(11.19)
… 4
, ‘1 ’ ·
(11.16)
· …
(11.21)
* 45,025 33,878
, (11.15)
* ,
(Affordable Care Act)’
, (compounding pharmacy)
(11.7)
In Drug Compound Act)’
- 13 -
, (fat tax) … (11.12)
* '11 10 1 16 ( 3) ,
, (11.5)
* ‘10 ’
… 18 3
- 60∼70
, iPS (11.5)
* iPS
5 , 10
, (iPS)
(11.6)
* '13 15
, (11.7)
* (10 ) 1 347
… (IHPS)
HIV (11.20)
* (PSTF), 15∼65
, ‘ ’ (11.1)
* (Auckland District Court) (Waitakere
District Court) ,
, SCI
PLoS One
,
NGO
(11.19, )
(11.28, )
(12.3, )
- , ‘2012 R&D ’(11. 26,
)
)
'(11.16, )
* , ’12 ’13
- , ‘ 2012 ’(11.21,
)
(11.20, )
’(11.19∼23)
- , ‘ (11.21,
)
(11.26, )
(11.19, )
* 14853 , 3016
- 15 -
9.1 7.1 10.9 -0.7 738 8.1 12.7 12.5 133
112,000. -2.2 18.0 26.0 2,303 1.0
7.1 10.8 8.5 -5.4 737 10.4 64.6 4.9 198
43,150. -7.2 9.7 26.0 1,337 6.4
7.0 -11.6 11.1 -7.3 587 8.4 3.2 15.1 121
149,000. -6.6 26.7 26.0 1,335 -2.8
6.7 2.8 7.9 -4.1 504 7.5 22.3 19.9 102
178,500. -5.6 21.6 26.0 1,511 -
5.1 -13.8 0.3 2.5 840 16.4 -2.5 10.2 143
129,500. 9.7789.6 26.0 1,919 0.9
2.8 54.0 65.3 5.9 1,376 49.4 43.9 45.4 1
26,000. 2.2 26.9 26.0 655 25.5
0.3 40.3 12.5 3.7 93 36.7 3.3 6.0 26
84,300. -2.8126.6 -260.7 117 20.6
0.1 51.7 -149 -4.7 464 480.2 1,447 2.2 315
5,290. -9.1 -8.1 -260.7 102 88.9
19
45
28,750. -4.5 74.5 86.9 791 6.3
1.0 -7.1 7.8 0.4 50 5.1 -6.4 1.5 165
10,250. -5.5 74.3 86.9 193 -40.8
0.4 15.7 23.4 -1.7 55 15.7 -1.3 1.8 131
18,100. 2.0 26.8 86.9 88 27.5
139
- 16 -
22.9 11.4 16.1 -0.4 734 3.2 10.8 76.9 33
1,315,000. 5.0 27.8 26.7 4,443 7.8
LG 20.0 14.2 12.1 0.1 435 2.2 11.1 103.1 22
660,000. 2.5 44.2 40.0 3,372 8.0
3.1 25.7 10.9 -1.2 20 0.7 33.7 8.7 156
84,000. -7.6 31.0 26.7 211 10.5
3.0 16.5 5.0 -1.1 144 4.8 11.2 5.8 185
29,800. -7.6 n.a. 26.7 659 2.6
1.8 13.7 4.9 -1.0 39 2.2 12.5 6.4 176
46,900. -8.6 55.4 26.7 368 16.5
* () 3 ‘11. 4. 1 ‘12. 3. 31
7,983 619.1 (7.7%)
11,203 434.8 (3.9%)
8,989 395.8 (4.4%)
5,017 73.7 (1.5%)
* R&D (, , , , ,
) +
, , )
- 17 -
(: , , %)
- - - - - -
1,000
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -